Tirzepatide vs retatrutide: how the next-generation GLP-1 actually compares
Retatrutide adds a third receptor target on top of tirzepatide's dual mechanism. Early data is striking — here's the honest read.
by Editorial team
Mechanism difference that matters
Tirzepatide hits GLP-1 and GIP. Retatrutide hits GLP-1, GIP, and glucagon receptors. Glucagon-receptor agonism increases energy expenditure — which is why retatrutide is producing weight loss numbers beyond what GLP-1 + GIP alone achieves.
Trial numbers
Retatrutide's phase 2 trial reported ~24% body weight reduction at the highest dose over 48 weeks. Tirzepatide's comparable data is ~22% over 72 weeks. Retatrutide also produced these numbers faster.
Caveat: retatrutide is still in trials. Approval, real-world side effect rates, and long-term safety are not yet established.
Side effect signal
Early retatrutide data shows side effects in the same family as tirzepatide (GI, fatigue), with a possibly more aggressive curve due to the glucagon agonism component. Slow titration is even more important here.